DexCom, Inc. (NASDAQ:DXCM) Stock Holdings Trimmed by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale decreased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 3.5% in the 3rd quarter, HoldingsChannel reports. The firm owned 850,305 shares of the medical device company’s stock after selling 30,711 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in DexCom were worth $56,976,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of DXCM. Crewe Advisors LLC bought a new position in DexCom in the 1st quarter valued at about $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of DexCom in the second quarter valued at approximately $25,000. Sachetta LLC increased its stake in shares of DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 171 shares during the period. DT Investment Partners LLC raised its holdings in DexCom by 492.2% during the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after purchasing an additional 315 shares in the last quarter. Finally, RiverPark Advisors LLC acquired a new stake in DexCom in the first quarter worth approximately $55,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

DXCM has been the topic of a number of research reports. Stifel Nicolaus boosted their price objective on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd. Baird R W cut shares of DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th. Canaccord Genuity Group restated a “buy” rating and set a $145.00 price objective on shares of DexCom in a research report on Tuesday, July 23rd. Royal Bank of Canada lowered their price objective on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday. Finally, Wells Fargo & Company increased their target price on shares of DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday. Six equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Stock Down 1.9 %

NASDAQ:DXCM opened at $73.44 on Monday. The business’s fifty day moving average price is $70.11 and its 200 day moving average price is $97.95. The firm has a market capitalization of $29.21 billion, a price-to-earnings ratio of 47.38, a PEG ratio of 2.26 and a beta of 1.18. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The firm’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.34 EPS. On average, sell-side analysts forecast that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Michael Jon Brown sold 652 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total value of $45,346.60. Following the transaction, the executive vice president now owns 66,249 shares in the company, valued at approximately $4,607,617.95. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,824 shares of company stock valued at $126,390. Corporate insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.